Literature DB >> 17112700

Gestational toluene exposure effects on spontaneous and amphetamine-induced locomotor behavior in rats.

Scott E Bowen1, Michael H Mohammadi, Jeffery C Batis, John H Hannigan.   

Abstract

Gestational Toluene Exposure Effects on Spontaneous and Amphetamine-Induced Locomotor Behavior in Rats. Bowen, S.E., Mohammadi, M.H., Batis, J.C., and Hannigan, J.H. Neurotoxicology and Teratology, XX, 2006. The abuse of volatile organic solvents (inhalants) continues to be a major health concern throughout the world. Toluene, which is found in many products such as glues and household cleaners, is among the most commonly abused organic solvents. The neurobehavioral teratogenic sequelae of solvent abuse (i.e., repeated, brief inhalation exposures to very high concentrations of solvents) have not been examined thoroughly. In a preclinical model of inhalant abuse, timed-pregnant Sprague-Dawley rats were exposed to 0, 8000, or 12,000 parts per million (ppm) for 15 min twice daily from gestation day 8 (GD8) through GD20. In the first experiment, separate groups of offspring were observed individually in an open-field on postnatal day 22 (PN22), PN42 or PN63. In the second experiment, other offspring given identical prenatal toluene exposures were observed in an "open-field" following an acute i.p. injection of amphetamine (0, 0.56, 1.78 mg/kg) on PN28. Automated measurements of distance traveled and ambulatory time were recorded. Prenatal toluene exposure resulted in small alterations in spontaneous activity compared to non-exposed rats. Prenatal exposure to 12,000 ppm toluene resulted in significant hyposensitivity to the locomotor stimulatory effects of the amphetamine challenge in male but not female rats on PN28. The results demonstrate that prenatal exposure to abuse patterns of high concentrations of toluene through inhalation can alter spontaneous and amphetamine-induced locomotor behavior in rats. The expression of these effects also appears to depend upon the postnatal age of testing. These results imply that abuse of organic solvents during pregnancy in humans may also produce long-lasting effects on biobehavioral development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17112700      PMCID: PMC1876668          DOI: 10.1016/j.ntt.2006.09.027

Source DB:  PubMed          Journal:  Neurotoxicol Teratol        ISSN: 0892-0362            Impact factor:   3.763


  49 in total

1.  Toluene abuse and neurologic impairment.

Authors:  L Fornazzari; D Riley; P Wu; P L Carlen
Journal:  Neurology       Date:  1987-02       Impact factor: 9.910

2.  Social and psychological factors underlying inhalant abuse.

Authors:  E R Oetting; R W Edwards; F Beauvais
Journal:  NIDA Res Monogr       Date:  1988

3.  Cerebellar, cortical and functional impairment in toluene abusers.

Authors:  L Fornazzari; D A Wilkinson; B M Kapur; P L Carlen
Journal:  Acta Neurol Scand       Date:  1983-06       Impact factor: 3.209

4.  Fetal solvents syndrome.

Authors:  C Toutant; S Lippmann
Journal:  Lancet       Date:  1979-06-23       Impact factor: 79.321

5.  Toluene abuse and renal tubular acidosis in pregnancy.

Authors:  T M Goodwin
Journal:  Obstet Gynecol       Date:  1988-05       Impact factor: 7.661

Review 6.  Adolescent pregnancy.

Authors:  Dianne S Elfenbein; Marianne E Felice
Journal:  Pediatr Clin North Am       Date:  2003-08       Impact factor: 3.278

7.  Effects of acute and chronic toluene inhalation on behavior and (3H)-serotonin binding in rat.

Authors:  S Yamawaki; T Segawa; K Sarai
Journal:  Life Sci       Date:  1982-06-07       Impact factor: 5.037

8.  Toluene abuse causes diffuse central nervous system white matter changes.

Authors:  N L Rosenberg; B K Kleinschmidt-DeMasters; K A Davis; J N Dreisbach; J T Hormes; C M Filley
Journal:  Ann Neurol       Date:  1988-06       Impact factor: 10.422

9.  Toluene embryopathy.

Authors:  J H Hersh; P E Podruch; G Rogers; B Weisskopf
Journal:  J Pediatr       Date:  1985-06       Impact factor: 4.406

10.  Metabolite alterations in basal ganglia associated with psychiatric symptoms of abstinent toluene users: a proton MRS study.

Authors:  Kiyokazu Takebayashi; Yoshimoto Sekine; Nori Takei; Yoshio Minabe; Haruo Isoda; Hiroyasu Takeda; Katsuhiko Nishimura; Kazuhiko Nakamura; Katsuaki Suzuki; Yasuhide Iwata; Harumi Sakahara; Norio Mori
Journal:  Neuropsychopharmacology       Date:  2004-05       Impact factor: 7.853

View more
  7 in total

1.  Review of toluene action: clinical evidence, animal studies and molecular targets.

Authors:  Silvia L Cruz; María Teresa Rivera-García; John J Woodward
Journal:  J Drug Alcohol Res       Date:  2014

Review 2.  Inhalant abuse among adolescents: neurobiological considerations.

Authors:  D I Lubman; M Yücel; A J Lawrence
Journal:  Br J Pharmacol       Date:  2008-03-10       Impact factor: 8.739

3.  Alterations in rat fetal morphology following abuse patterns of toluene exposure.

Authors:  Scott E Bowen; Susan Irtenkauf; John H Hannigan; Adrianne L Stefanski
Journal:  Reprod Toxicol       Date:  2009-01-21       Impact factor: 3.143

4.  Differential effects of inhaled toluene on locomotor activity in adolescent and adult rats.

Authors:  Jeffery C Batis; John H Hannigan; Scott E Bowen
Journal:  Pharmacol Biochem Behav       Date:  2010-07-15       Impact factor: 3.533

5.  Maternal and fetal blood and organ toluene levels in rats following acute and repeated binge inhalation exposure.

Authors:  Scott E Bowen; John H Hannigan; Susan Irtenkauf
Journal:  Reprod Toxicol       Date:  2007-06-26       Impact factor: 3.143

6.  Decreased sensitivity in adolescent vs. adult rats to the locomotor activating effects of toluene.

Authors:  Scott E Bowen; Jonathan D Charlesworth; Mary E Tokarz; M Jerry Wright; Jenny L Wiley
Journal:  Neurotoxicol Teratol       Date:  2007-08-17       Impact factor: 3.763

Review 7.  Inhalant use and inhalant use disorders in the United States.

Authors:  Matthew O Howard; Scott E Bowen; Eric L Garland; Brian E Perron; Michael G Vaughn
Journal:  Addict Sci Clin Pract       Date:  2011-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.